Abstract
P-glycoprotein (PgP), a transmembrane protein, has been associated with multiple drug resistance. We examined 42 patients with chronic lymphocytic leukemia immunohistochemically using the monoclonal antibody JSB-1 to determine the prevalence of PgP expression and its relationship with chemotherapy exposure. Of the 42 patients, 31 (74%) had detectable PgP. No relationship was found between PgP expression, patient age, duration of disease or stage. Moderate and strong intensity staining was found in 22% of untreated patients versus 56% patients treated with chemotherapy (p<0.05). Temporal fluctuations in P-glycoprotein staining intensity was seen in 6 of 7 cases which paralleled the initiation or withdrawal of the therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
